The COX-2 selective inhibitor-independent COX-2 effect on colon carcinoma cells is associated with the delta1/notch1 pathway

Digestive Diseases and Sciences

Volumn 53, Issue 8, 2008, Pages 2195-2203

  Zhang, Hui ^a   Ye, Yingjiang ^a   Bai, Zhigang ^a   Wang, Shan ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Apoptosis; Colon carcinoma; Cyclooxygenase 2 inhibitor; Notch signal transduction; Proliferation

Indexed keywords

3 (4 AMINOBUTYRYL) 1,2 DILINOLENOYLGLYCEROL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; GAMMA SECRETASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NOTCH1 RECEPTOR; PROSTAGLANDIN E2; PROTEIN DELTA1; TRANSCRIPTION FACTOR HES 1;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL NUCLEUS; CELL PROLIFERATION; COLON CARCINOMA; COLORIMETRY; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; DRUG INHIBITION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANTINEOPLASTIC AGENTS; APOPTOSIS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BLOTTING, WESTERN; CELL PROLIFERATION; COLONIC NEOPLASMS; COLORIMETRY; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; DIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HOMEODOMAIN PROTEINS; HT29 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE PROTEINS; NF-KAPPA B P52 SUBUNIT; NITROBENZENES; RECEPTOR, NOTCH1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SULFONAMIDES; TIME FACTORS;

EID: 46449090624     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-007-0139-0     Document Type: Article

References (34)

1. Timothy AC (2002) Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet Oncol 3:166-174
2. Song X, Lin HP, Johnson AJ, et al. (2002) Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst 94:585-591
3. Ming L, Xiuyuan W, Xu XC (2001) Inhibition of apoptosis in colon cancer cells by cyclooxygenase-2 inhibitor NS-398 through a cytochrome c-dependent pathway. Clin Cancer Res 7:1010-1016
4. Takahashi T, Ogawa Y, Kitaoka K, et al. (2005) Selective COX-2 inhibitor regulates the MAP kinase signaling pathway in human osteoarthritic chondrocytes after induction of nitric oxide. Int J Mol Med 15:213-219
5. Gao J, Niwa K, Takemura M, et al (2005) Significant anti-proliferation of human endometrial cancer cells by combined treatment with a selective COX-2 inhibitor NS398 and specific MEK inhibitor U0126. Int J Oncol 26:737-744
6. Wu J, Xia HH, Tu SP (2003) 15-Lipoxygenase-1 mediates cyclooxygenase-2 inhibitor-induced apoptosis in gastric cancer peroxisome proliferator-activated receptors. Carcinogenesis 24:243-247
7. Nakata H, Uemura Y, Kobayashi M, et al. (2003) Cyclooxygenase-2 inhibitor NS-398 suppresses cell growth and constitutive production of granulocyte-colony stimulating factor and granulocyte macrophage-colony stimulating factor in lung cancer cells. Cancer Sci 94:173-180
8. Subhashini J, Mahipal SV, Reddanna P, et al. (2005) Anti-proliferative and apoptotic effects of celecoxib on human chronic myeloid leukemia in vitro. Cancer Lett 224:31-43
9. Zhang Z, Lai GH, Sirica AE, et al. (2004) Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation. Hepatology 39:1028-1037
10. Artavanis-Tsakonas SR, Rand MD, Lake RJ (1999) Notch signaling: cell fate control and signal integration in development. Science 284:770-776
11. Mumm JS, Kopan R (2000) Notch signaling: from the outside in. Dev Biol 228:151-165
12. Robbins J, Blondel BJ, Gallahan D, Callahan R (1992) Mouse mammary tumor gene int-3: a member of the notch gene family transforms mammary epithelial cells. J Virol 66:2594-2599
13. Gallahan D, Jhappan C, Robinson G, Hennighausen L, et al. (1996) Expression of a truncated Int3 gene in developing secretory mammary epithelium specifically retards lobular differentiation resulting in tumorigenesis. Cancer Res 56:1775-1785
14. Capobianco AJ, Zagouras P, Blaumueller CM, Artavanis-Tsakonas S, Bishop JM (1997) Neoplastic transformation by truncated alleles of human NOTCH1/TAN1 and NOTCH2. Mol Cell Biol 17:6265-6273
15. van Es JH, van Gijn ME, Riccio O, et al. (2005) Notch/g-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435:959-963
16. Weijzen S, Rizzo P, Braid M, et al. (2002) Activation of Notch-1 signaling maintains the neoplastic phenotype in human Rastransformed cells. Nat Med 8:979-986
17. Patel NS, Dobbie MS, Rochester M, et al. (2006) Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer. Clin Cancer Res 12:4836-4844
18. Duan L, Yao J, Wu X, Fan M (2006) Growth suppression induced by Notch1 activation involves Wnt-beta-catenin down-regulation in human tongue carcinoma cells. Biol Cell 98:479-490
19. Wang Z, Zhang Y, Banerjee S, et al. (2006) Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer 106:2503-2513
20. De Strooper B, Annaert W, Cuperset P, et. al. (1999) Presenilin-1- dependent g-secretase-like protease mediates release of Notch intracellular domain. Nature 398:518-522
21. Kopan R, Goate A (2000) A common enzyme connects Notch signaling and Alzheimer's disease. Genes Dev 14:2799-2806
22. Wong GT, Manfra D, Poulet FM, et al. (2004) Chronic treatment with the g-secretase inhibitor LY-411, 575 inhibits b-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 279:12876-12882
23. Milano J, McKay J, Dagenais C, et al. (2004) Modulation of notch processing by g-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci 1:341-358
24. Searfoss GH, Jordan WH, Calligaro DO, et al. (2003) Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional g-secretase inhibitor. J Biol Chem 278:46107-46116
25. Baron M (2003) An overview of the Notch signalling pathway. Semin Cell Dev Biol 14:113-119
26. Grabher C, von Boehmer H, Look AT (2006) Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukemia. Nat Rev Cancer 6:347-359
27. Ferres-Marco D, Gutierrez-Garcia I, Vallejo DM, et al. (2006) Epigenetic silencers and Notch collaborate to promote malignant tumours by Rb silencing. Nature 439:430-436
28. Arumugam TV, Chan SL, et al. (2006) Gamma secretase-mediated Notch signaling worsens brain damage and functional outcome in ischemic stroke. Nat Med 12:621-623
29. Kim SJ, Seo JH, Lee YJ, et al. (2005) Autocrine vascular endothelial growth factor/vascular endothelial growth factor receptor-2 growth pathway represents a cyclooxygenase-2-independent target for the cyclooxygenase-2 inhibitor NS-398 in colon cancer cells. Oncology 68:204-211
30. Heitzler P, Bourouis M, Ruel L, et al. (1996) Genes of the Enhancer of split and achaete-scute complexes are required for a regulatory loop between Notch and Delta during lateral signalling in Drosophila. Development 122:161-171
31. Oellers N, Dehiom M, Knustm E (1994) bHLH proteins encoded by the Enhancer of split complex of Drosophila negatively interfere with transcriptional activation mediated by proneural genes. Mol Gen Genet 244:465-473
32. Johnson AJ, Hsu AL, Lin HP (2002) The cyclo-oxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks. Biochem J 366:831-837
33. Miele L, Miao H, Nickoloff BJ (2006) NOTCH signaling as a novel cancer therapeutic target. Curr Cancer Drug Targets 6:313-323
34. Mungamuri SK, Yang X, Thor AD, et al (2006) Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res 66: 4715-4724